Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.58 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.58 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.58 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.58 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.52 |
| ▸ | FEN1 | P39748 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8792040 | 0.90 | ERCC5 (0.62) | PARP10PARP15ALDH1A1KMT2APARP14 | |
| SCHEMBL564383 | 0.86 | PARP10 (0.63) | PARP10PARP15ALDH1A1KMT2APARP14 | |
| Hydrochloric Acid SCHEMBL563830 | 0.84 | PARP10 (0.61) | PARP10PARP15ALDH1A1KMT2APARP14 | |
| Hydrochloric Acid SCHEMBL13738814 | 0.83 | GSK3B (0.42) | ALDH1A1KMT2AHPGDMAPTRAB9A | |
| SCHEMBL182867 | 0.83 | HDAC3 (0.66) | PARP10ALDH1A1PARP4MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL335070 | 0.81 | HDAC3 (0.63) | PARP10ALDH1A1PARP4MAPTRAB9A | |
| SCHEMBL9056179 | 0.79 | ELANE (0.56) | ALDH1A1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL883159 | 0.78 | SMN1; SMN2 (0.50) | ALDH1A1HPGDMAPTRAB9AERCC5 | |
| SCHEMBL11660630 | 0.78 | ALOX15 (0.57) | ALDH1A1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20491355 | 0.78 | ALOX15 (0.56) | ALDH1A1KMT2ARAB9ATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327743-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND METHOD FOR MANUFACTURING SAME | JNC CORP (JP) | 2017-11-16 | — | — | US | disclosed |
| US-9771519-B2 | Liquid crystal display device and method for manufacturing same | JNC CORPORATION (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170227820-A1 | LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170199432-A1 | LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-07-13 | — | — | US | disclosed |
| US-20170114277-A1 | LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-04-27 | — | — | US | disclosed |
| US-20160369168-A1 | LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-22 | — | — | US | disclosed |
| US-20150275089-A1 | LIQUID CRYSTAL DISPLAY ELEMENT AND METHOD FOR MANUFACTURING SAME | JNC PETROCHEMICAL CORPORATION (JP) | 2015-10-01 | — | — | US | disclosed |
| EP-2414350-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8796466-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2012039717-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| WO-2010117635-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | PARP10 4090/4885PARP15 4303/4885ALDH1A1 2120/4885 |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | PARP10 4090/4885PARP15 4303/4885ALDH1A1 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.